Chinese herbal products (CHPs) containing Radix bupleuri are often prescribed for chronic hepatitis. There have been no epidemiological studies in populations with hepatitis B virus (HBV) infection. Our study was conducted to determine the association between the use of CHPs containing Radix bupleuri and the risk of hospitalisation related to liver injury among HBV-infected patients in Taiwan.
From a total of 639,779 patients with diagnoses related to HBV infection, we included hospitalised adult cases with a primary diagnosis of liver injury in the database of Taiwan's national health insurance during the period 1997–2004. Case-control and case-crossover designs were used to assess the risk of hospitalisation with conditional logistic regression models constructed and adjusted for 270 conventionally hepatotoxic drugs. Cumulative doses of these CHPs and Radix bupleuri were assessed for any dose-response relationship.
In total, we collected 1,080 cases fulfilled the inclusion criteria. In the case-control design, the adjusted odds ratio was 1.90 (95% confidence interval [CI]: 1.30 to 2.77). The risks from prescribing the CHPs Xiao-Chai-Hu-Tang and Long-Dan-Xie-Gan-Tang were significantly high, and dose-response relationships were found. The risk of adding each 19 gm dose of Radix bupleuri was 2.19 (95% CI: 1.66 to 2.89). The results using the case-crossover design remained similar.
Prescribing Xiao-Chai-Hu-Tang, Long-Dan-Xie-Gan-Tang, or CHPs containing more than 19 gram of Radix bupleuri in HBV-infected patients might increase their risks of liver injury. Further studies are indicated to corroborate the above findings.
Citation: Lee C-H, Wang J-D, Chen P-C (2011) Risk of Liver Injury Associated with Chinese Herbal Products Containing Radix bupleuri in 639,779 Patients with Hepatitis B Virus Infection. PLoS ONE 6(1): e16064. doi:10.1371/journal.pone.0016064
Editor: Man-Fung Yuen, The University of Hong Kong, Hong Kong
Received: September 17, 2010; Accepted: December 7, 2010; Published: January 12, 2011
Copyright: © 2011 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by the National Science Council (NSC98-2314-B-002-129), Taiwan (http://web1.nsc.gov.tw/mp.aspx?mp=7). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
An increasing number of herbal remedies are now being reported as hepatotoxic, with such reports on Chinese herbal products (CHPs) recently including a variety of types, such as Radix scutellariae, Radix bupleuri, Herba ephedrae, Radix polygoni multiflori, Atractylodis macrocephalae rhizoma, Radix glycyrrhizae, Radix paeoniae, Cortex moutan, and Cortex dictamni.,  However, regular users seem still to regard these remedies as ‘natural’ and nontoxic. CHPs are also prescribed for chronic hepatitis in Taiwan, especially in patients with hepatitis B virus (HBV) infection.
CHPs containing Radix bupleuri, such as Da-Chai-Hu-Tang (Dai-saiko-to, TJ-8) and Xiao-Chai-Hu-Tang (syo-saiko-to, TJ-9) have been reported to induce hepatotoxicity., , ,  Among them, Xiao-Chai-Hu-Tang is often prescribed to treat HBV infection and the usual posology for Radix bupleuri is doses of 3–9 g/day. , ,  However, another study undertaken in Hong Kong found that 32% of the patients with HBV infection had used CHPs, and 9% of them experienced moderate to severe side effects.
Drug- or herb-induced liver injury is usually difficult to detect.,  A post-market pharmacoepidemiologic survey in a large automated database provides a method to detect the risk associated with herbal medications. The National Health Insurance (NHI) program in Taiwan is a universal system of compulsory health insurance that has been providing coverage for 96.2% of the population of Taiwan since the end of 2000. The Taiwanese government reimburses not only general healthcare expenditures but also the costs of prescriptions for CHPs (amounting to 780 different kinds of single herbs and mixed formulae in concentrated extract form).  This computerised database of CHPs provides us with an invaluable opportunity to undertake a population-based study.
This study was conducted to determine the association between the use of CHPs containing Radix bupleuri and the risk of hospitalisation related to liver injury among HBV-infected patients in Taiwan.
With strict confidentiality guidelines being closely followed in accordance with personal electronic data protection regulations, The National Health Research Institutes of Taiwan anonym zed and maintained the NHI reimbursement data as files suitable for research. The identification numbers of all individuals with reimbursement data in the NHI database were encrypted to protect the privacy of the individuals. In addition, this study was also approved by the Ethics Review Board at the National Taiwan University College of Public Health.
NHI databases in Taiwan
The dataset for the study was obtained from the NHI Research Database, which is a nationwide, population-based, reimbursement database and all the personal identification has been encrypted for research use. The files are comprised of comprehensive information on all medications prescribed to all insured individuals. We conducted this study on both outpatient visits and inpatient admission databases from January 1, 1997 through December 31, 2004.
Cases included hospitalised patients who were older than 18 years of age and who suffered from liver injuries with diagnoses related to HBV infection coded as 070.2, 070.3 and V02.61 by the International Classification of Diseases, 9th Revision (ICD-9). Because liver diseases were the important health problems for our country, the government pay more intention for this health issue and make the guideline for diagnosis.  However, to prevent any case misclassification, we only included incident cases with a primary diagnosis of liver injury, and we excluded cases with other diagnoses on admission or cases reported only from outpatient clinics. Primary diagnoses of liver injury coded by the ICD-9 included acute and sub-acute necrosis of the liver (570), toxic hepatitis (573.3), other specified disorders of liver (573.8), and unspecified disorders of liver (573.9). Moreover, we excluded patients who had been diagnosed with the following conditions at any time before admission: viral hepatitis A, viral hepatitis C, other viral hepatitis (070.0, 070.1, 070.4, 070.5, 070.6, 070.7, and 070.9), and viral hepatitis carriers (V02.60, V02.62, and V02.69); cytomegalovirus and coxsackie virus diseases and infectious mononucleosis (573.1 to 573.2); cholelithiasis (574.0 to 574.9); alcoholic liver diseases, chronic hepatitis, cirrhosis of liver without mention of alcohol, biliary cirrhosis, Other chronic nonalcoholic liver disease, unspecified chronic liver disease without mention of alcohol (571.0 to 571.9); abscess of the liver, portal pyemia, hepatic coma, portal hypertension, hepatorenal syndrome, and chronic passive congestion of the liver (572.0 to 573.0); malignant neoplasm of liver and intrahepatic bile ducts (155.0 to 155.2), liver metastasis (197.7), carcinoma in situ of the liver and biliary system (230.8); and liver disorders during pregnancy (646.7).
Selection of referents in the case-control and case-crossover designs
First, we analysed the datasets using a case-control design. Four control subjects or referents for each case were randomly selected by matching the age and gender from the same population with HBV infection who did not have previous diagnoses of either liver injury or any of the diseases that met the exclusion criteria for cases. Namely, we first included all people with HBV-infected diagnosis, excluded those with aforementioned diagnoses, and then randomly drew 4 age- and gender- matched controls for each case. In the case-crossover design, we set four referent exposure windows before the recent exposure window and set 90 days between them to prevent any carryover effect. We applied the 30-day exposure windows in both designs.
CHPs containing Radix bupleuri and covariates
We selected all CHPs containing Radix bupleuri as our target drugs. We then calculated the cumulative dose of CHPs prescribed during each exposure window. Otherwise, we estimated the crude dosage of Radix bupleuri in the CHPs in terms of both weight and concentrated proportions, based on the concentrated mixed products manufactured by different CHP companies and translated to the dose of crude herbs by concentrated ratio. Within a commercial brand of Xiao-Chai-Hu-Tang, for example, the registered weight proportion of Radix bupleuri was 0.33, whilst the concentrated proportion was 4 and added the equal weight starch; thus, a final product containing 1.0 gm of such a concentrated CHP would be equivalent to 0.67 gm of Radix bupleuri in crude form. The cumulative dosage of Radix bupleuri within the CHPs was also calculated by adding together the total dosage prescribed during each exposure windows. Then we stratified with the median dose of the cumulative dosages to test for trends of dose-response. Other hepatotoxic drugs and co-morbidities were considered as covariates in the models. We undertook a search of the Micromedex® database  for a total of 702 generic drugs that had been previously reported as having any connection with hepatotoxicity. The NHI in Taiwan regularly reimbursed for 270 of these generic drugs. We calculated the scores of Charlson Comorbidity Index by using ICD-9 codes to determine the condition of 1-year comorbidity.
The use of CHPs containing Radix bupleuri by each case subject during the exposure window was contrasted with the use of the same CHPs for the same duration by the four matched control subjects. The odds ratio (OR) was calculated for the exposure-odds of case subjects and control subjects and denoted as a case-control estimate. In the case-crossover design, the prevalence of CHPs containing Radix bupleuri during the single recent exposure window was contrasted with the prevalence over four reference windows for the same case subject. Because the study designs included one case matched with four controls or one recent exposure window matched with four reference exposure windows, we analysed the data through a conditional logistic regression model to explore the association between hospitalisation and CHPs containing Radix bupleuri. By adjusting two covariates in the case-control design (the Charlson co-morbidity index scores and the frequency of the time-variant hepatotoxic drugs during each exposure window) and by adjusting the latter in the case-crossover design, we obtained the adjusted ORs. The data analysis was performed and modelled to calculate ORs and 95% CIs using SAS version 9.13 software (SAS Institute Inc., Cary, NC).
After conforming to the inclusion and exclusion criteria from the population with 639,779 patients with HBV infection, the sample was comprised of 1,080 cases with at least one 30-day referent exposure window during the study period. Among them, 13.4% were 60 year of age or older, with a mean age of 40.2±14.6 years. Table 1 shows that case subjects had larger Charlson co-morbidity index scores and more pre-admission use of hepatotoxic drugs and CHPs per person than control subjects had.
Table 1. Characteristics, co-morbidities, prescriptions and time-dependent hepatotoxic drugs for study subjects with viral hepatitis B infection, 1997–2004.doi:10.1371/journal.pone.0016064.t001
In the case-control design, the adjusted OR during the 30-day window was 1.90 (95% Confidence Interval (CI): 1.30 to 2.77) between all products with Radix bupleuri and admissions with liver injury. The risks from Xiao-Chai-Hu-Tang and Long-Dan-Xie-Gan-Tang were significantly high, and the tests for trends in the dose-response reaction were significant. The additional risk incurred by adding each 19 gm dose of Radix bupleuri was 2.19 (CI: 1.66 to 2.89). The results using the case-crossover design remained similar.
Although our study found that the prescription of two CHPs containing Radix bupleuri, Xiao-Chai-Hu-Tang and Long-Dan-Xie-Gan-Tang, increased the risk of hospitalisation for liver injury among HBV-infected subjects, it does not necessarily follow that the association might be causal. We have following arguments to suspect that the hypothesis is plausible.
The risk trends were consistent in both designs—case-control and case crossover, and there seems a dose-response relationship, as summarized in the Table 2. To prevent potential confounding by misdiagnosis, we deliberately included only patients who were hospitalised and excluded other possible causes of hepatobiliary diseases, including all other hepatitis-related infections, alcohol-related liver disorders, cholelithiasis and de-compensated hepatic conditions, as these conditions might make patients more likely to suffer liver injury from exposure to potentially hepatotoxic drugs. Our estimates were more conservative as we did not include the above cases. Because we did not have any direct access to the original clinical data, our study was necessarily limited to the more severe cases resulting in hospitalisations, which may increase the validity of the diagnosis but undoubtedly resulted in an underestimation of hepatotoxicity with only mild manifestations.
Table 2. Number of exposed subjects with viral hepatitis B in the 30-day windows and adjusted odds ratios between hospitalisations with liver injury and Chinese herbal products with Radix bupleuri by case-control and case-crossover designs, 1997–2004.doi:10.1371/journal.pone.0016064.t002
Another potential explanation is the confounding by indication, as the two major CHPs were frequently prescribed by Chinese medicine doctors to treat hepatitis. However, the most frequently prescribed CHP containing Radix bupleuri for subjects with HBV infection was Jia-Wei-Xia-Yao-San and the adjusted OR was 1.87 (CI: 0.69 to 5.06) by case-crossover design (Table 2). Moreover, prescriptions of all the other CHPs containing Radix bupleuri combined together did not show a significantly higher risk of liver injury, either. As these products were usually prescribed to HBV-infected patients, or, supposedly to be associated with HBV infection, the results of no existing association in other CHPs might serve as a contrast against the possibility of confounding by indication. However, since the number for each individual CHPs is small, we cannot draw a strong inference.
To test the potential dose-response relationship, we summed up the cumulative prescribed doses of Radix bupleuri for every window period of each patient, and then stratified the groups into 0, below and above the median dose of 19 gm. We detected a statistically significant linear trend between the increased dose and hospitalization related to liver injury (Table 2). We conducted further sensitivity analyses by stratification to clarify the misclassifications and potential confounders in the case-crossover design. The results reveal no significant changes in the ORs of the subgroups stratified by different prescribing conditions, matched patterns and co-morbidities. Although the medications being studied were co-prescribed with seven potentially hepatotoxic drugs, the results reveal no significant contributions of drug-drug interactions. (Appendix S1) Since there is no other alternative explanation for the reasons of hospitalisation, we tentatively conclude that the association between liver injury and CHPs containing Radix bupleuri in HBV-infected patients exists and deserves our attention.
In Japan, Xiao-Chai-Hu-Tang and other CHPs containing Radix bupleuri produced no significant effect of acute and chronic toxicity on rats. However, these animals were not suffering from HBV infection. With a retrospective study of reviewing HBV-infected cases with liver injury, Yuen et al. found 45 cases with suspected CHP-associated liver injury.  A hospital-based questionnaire survey found 10 of 116 patients who had taken CHPs experienced side effects. But they did not explore the detailed active ingredients in the exposed CHPs. The only one clinical trial that involved applying Xiao-Chai-Hu-Tang in 16 HBV-infected patients with cirrhosis for 60 months (or, a total of 80 person years) did not detect any side effect. Our study is conducted on a nation-wide basis and followed for 7 years, of which we collected 281,982 person-years of exposure to Xiao-Chai-Hu-Tang and there were a total of 224 cases with liver injury that required hospitalisation, which reveals an annual incidence rate of 7.94×10−4 per year, while that of Long-Dan-Xie-Gan-Tang is 5.96×10−4.
Potential limitations of this study, including unmeasured confounders, use of other out-of-pocket drugs, and patient compliance should also be discussed. First, the NHI reimburses for prescribed CHPs in concentrated extract form only, whereas herbal stores can sell raw herbs for patients to self-prepare decoction, according to the Pharmaceutical Affairs Law in Taiwan. The potential impact of current practices should not be ignored. However, as self-purchased raw herbs were not regularly reimbursed, people usually take them once in a while or when the CHPs fails to improve the symptom. Thus, the cumulative dose is usually small after stratification for different window periods. Furthermore, if such habits among patients remained unchanged within a 2-year period, the case-crossover design might eliminate this potential confounding, taking the advantage of each patient serving as his/her own control. Finally, this study also presumed that all prescribed medications were actually taken by subjects as prescribed, which may overestimate the actual ingested dosage, as some degree of noncompliance is always expected.
Our study found that HBV-infected subjects using Xiao-Chai-Hu-Tang and Long-Dan-Xie-Gan-Tang had an increased risk of liver injury, and there was a statistically significant linear trend of dose-response for the cumulative prescribed doses of Radix bupleuri. Thus, we recommend that physicians should carefully monitor hepatic function in the subjects who are taking these CHPs regularly. Moreover, if liver injury occurs, Xiao-Chai-Hu-Tang and Long-Dan-Xie-Gan-Tang should be considered as the potential sources of hepatotoxicity. However, further mechanistic research on the hepatotoxicity of Radix bupleuri in the presence of HBV infection is warranted.
Sensitivity analysis of adjusted odds ratios between hospitalisations with liver injury and Xiao-Chai-Hu-Tang and Long-Dan-Xie-Gan-Tang stratified by subgroups of matched patterns, prescribing conditions, co-morbidities and co-prescriptions by case-crossover design, 1997–2004.
Conceived and designed the experiments: PCC JDW CHL. Performed the experiments: CHL. Analyzed the data: CHL. Contributed reagents/materials/analysis tools: CHL. Wrote the paper: PCC JDW CHL.
- 1. Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M (1995) Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang). Dig Dis Sci. 40(8): 1845–1848.
- 2. Borum ML (2001) Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol 96(5): 1654–1655.
- 3. Park GJ, Mann SP, Ngu MC (2001) Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. J Gastroenterol Hepatol. 16(1): 115–117.
- 4. Melchart D, Linde K, Weidenhammer W, Hager S, Shaw D, et al. (1999) Liver enzyme elevations in patients treated with traditional Chinese medicine. JAMA 282(1): 28–29.
- 5. Kane JA, Kane SP, Jain S (1995) Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 36(1): 146–147.
- 6. Allen BR, Hollman A, Jones R, Harper JI, Davies EG, et al. (1990) Chinese herbs for eczema. Lancet 336(8708): 177.
- 7. Lee CH, Chen JJ, Liang WM (2006) Attitudes and intentions of patients toward integrated Chinese and Western medicine in Taiwan. J Altern Complement Med 12(3): 233–236.
- 8. Chen FP, Kung YY, Chen YC, Jong MS, Chen TJ, Chen FJ, et al. (2008) Frequency and pattern of Chinese herbal medicine prescriptions for chronic hepatitis in Taiwan. J Ethnopharmacol 117(1): 84–91.
- 9. Chen CJ, Wang LY, Chien YC (2004) News from Taiwan. Hepatology 39(5): 1196.
- 10. Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, et al. (1997) Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 92(4): 703–704.
- 11. Mantani N, Kogure T, Sakai S, Goto H, Shibahara N, et al. (2002) Incidence and clinical features of liver injury related to Kampo (Japanese herbal) medicine in 2,496 cases between 1979 and 1999: problems of the lymphocyte transformation test as a diagnostic method. Phytomedicine 9(4): 280–287.
- 12. Hsu LM, Huang YS, Tsay SH, Chang FY, Lee SD (2006) Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang. J Chin Med Assoc 69(2): 86–88.
- 13. Modi AA, Wright EC, Seeff LB (2007) Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review. Antivir Ther 12(3): 285–295.
- 14. World health organization. (1999) WHO monographs on medicinal plants (Radix bupleuri), http://apps.who.int/medicinedocs/en/d/Js2200e/9.html#Js2200e.9. Accessed October 5, 2010.
- 15. Wong VW, Law MY, Hui AY, Lo AO, Li CY, et al. (2005) A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. Complement Ther Med 13(3): 175–182.
- 16. Larrey D (2002) Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 22(2): 145–155.
- 17. Haller CA, Dyer JE, Ko R, Olson KR (2002) Making a diagnosis of herbal-related toxic hepatitis. West J Med 176(1): 39–44.
- 18. KC W (2000) The Turnover Rate of Marker Constituents in Chinese Herbal Medicine. J Food Drug Anal 8: 270–277.
- 19. National Health Research Institutes. (2003) National Health Insurance Research database. http://www.nhri.org.tw/nhird/date_01.html#_edn1. Accessed January 3, 2009.
- 20. National Health Research Institutes. (2003) National Health Insurance Research database. http://www.nhri.org.tw/nhird/date_01.html#_edn1. Accessed January 8, 2010.
- 21. Centers for Disease Control and Prevention, Atlanta, Georgia, (1979) International Classification of Diseases, Ninth Revision (ICD-9). http://www.cdc.gov/nchs/icd/icd9.htm. Accessed October 18, 2009.
- 22. Centers for Disease Control. Department of Health, Taiwan. (2008) Guideline for Communicable Disease Surveillance. http://www.cdc.gov.tw/public/data/92271549671.pdf Accessed October 18, 2010.
- 23. MICROMEDEX (2006) Healthcare Series, Vol.127 [internet database]. Greenwood Village, CO: Thomson Healthcare.
- 24. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6): 613–619.
- 25. Ikegami F, Sumino M, Fujii Y, Akiba T, Satoh T (2006) Pharmacology and toxicology of Bupleurum root-containing Kampo medicines in clinical use. Hum Exp Toxicol 25(8): 481–494.
- 26. Yuen MF, Tam S, Fung J, Wong DK, Wong BC, et al. (2006) Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Aliment Pharmacol Ther 24(8): 1179–1186.
- 27. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, et al. (1995) Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 76(5): 743–749.